Release date: 25 November 2009
Promoter – Financial Intermediary
Recordati Industria Chimica e Farmaceutica S.p.A. (Recordati), an Italian pharmaceutical company, and its controlled companies.
Location
Description
The project concerns investments in Research, Development and Innovation (RDI) related to the development of new drug entities within the cardiovascular and urogenital therapeutic areas, as well as the the development of new drugs for the treatment of rare diseases.
Objectives
Further development of Recordati portfolio of pharmaceutical products to expand their field of application and enhance their performance.
Sector(s)
Proposed EIB finance (Approximate amount)
Up to EUR 55 million.
Total cost (Approximate amount)
Estimated at EUR 113 million.
Environmental aspects
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities making use of existing laboratories. Thus an Environmental Impact Assessment (EIA) according to the EU Directive 97/11, as amended by Directive 2003/35, is not required.
Procurement
Procurement is expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project’s due diligence.
Status
Signed - 30/11/2010
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).